{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:04:53Z","timestamp":1793045093647,"version":"4.5.0"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,2,23]],"date-time":"2010-02-23T00:00:00Z","timestamp":1266883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,2,23]],"date-time":"2010-02-23T00:00:00Z","timestamp":1266883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1038\/nrrheum.2010.4","type":"journal-article","created":{"date-parts":[[2010,2,23]],"date-time":"2010-02-23T00:53:12Z","timestamp":1266886392000},"page":"232-241","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":812,"title":["IL-1 pathways in inflammation and human diseases"],"prefix":"10.1038","volume":"6","author":[{"given":"Cem","family":"Gabay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Lamacchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaby","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,2,23]]},"reference":[{"key":"BFnrrheum20104_CR1","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1152\/physrev.1960.40.3.580","volume":"40","author":"E Atkins","year":"1960","unstructured":"Atkins, E. Pathogenesis of fever. Physiol. Rev. 40, 580\u2013646 (1960).","journal-title":"Physiol. Rev."},{"key":"BFnrrheum20104_CR2","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1096\/fasebj.8.15.8001745","volume":"8","author":"CA Dinarello","year":"1994","unstructured":"Dinarello, C. A. The interleukin-1 family: 10 years of discovery. FASEB J. 8, 1314\u20131325 (1994).","journal-title":"FASEB J."},{"key":"BFnrrheum20104_CR3","doi-asserted-by":"publisher","first-page":"7907","DOI":"10.1073\/pnas.81.24.7907","volume":"81","author":"PE Auron","year":"1984","unstructured":"Auron, P. E. et al. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc. Natl Acad. Sci. USA 81, 7907\u20137911 (1984).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum20104_CR4","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/315641a0","volume":"315","author":"CJ March","year":"1985","unstructured":"March, C. J. et al. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature 315, 641\u2013647 (1985).","journal-title":"Nature"},{"key":"BFnrrheum20104_CR5","first-page":"77","volume":"5","author":"AC Webb","year":"1986","unstructured":"Webb, A. C. et al. Interleukin-1 gene (IL1) assigned to long arm of human chromosome 2. Lymphokine Res. 5, 77\u201385 (1986).","journal-title":"Lymphokine Res."},{"key":"BFnrrheum20104_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0378-1119(87)90398-2","volume":"52","author":"G Bensi","year":"1987","unstructured":"Bensi, G. et al. Human interleukin-1 beta gene. Gene 52, 95\u2013101 (1987).","journal-title":"Gene"},{"key":"BFnrrheum20104_CR7","doi-asserted-by":"publisher","first-page":"9667","DOI":"10.1073\/pnas.86.24.9667","volume":"86","author":"JP Priestle","year":"1989","unstructured":"Priestle, J. P., Sch\u00e4r, H. P. & Gr\u00fctter, M. G. Crystallographic refinement of interleukin 1 beta at 2.0 A resolution. Proc. Natl Acad. Sci. USA 86, 9667\u20139671 (1989).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum20104_CR8","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1021\/bi00463a009","volume":"29","author":"BJ Graves","year":"1990","unstructured":"Graves, B. J. et al. Structure of interleukin 1 alpha at 2.7-A resolution. Biochemistry 29, 2679\u20132684 (1990).","journal-title":"Biochemistry"},{"key":"BFnrrheum20104_CR9","doi-asserted-by":"publisher","first-page":"7245","DOI":"10.1073\/pnas.90.15.7245","volume":"90","author":"FT Stevenson","year":"1993","unstructured":"Stevenson, F. T., Bursten, S. L., Fanton, C., Locksley, R. M. & Lovett, D. H. The 31-kDa precursor of interleukin 1 alpha is myristoylated on specific lysines within the 16-kDa N-terminal propiece. Proc. Natl Acad. Sci. USA 90, 7245\u20137249 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum20104_CR10","doi-asserted-by":"crossref","first-page":"12162","DOI":"10.1016\/S0021-9258(18)98874-5","volume":"266","author":"LM Carruth","year":"1991","unstructured":"Carruth, L. M., Demczuk, S. & Mizel, S. B. Involvement of a calpain-like protease in the processing of the murine interleukin 1\u03b1 precursor. J. Biol. Chem. 266, 12162\u201312167 (1991).","journal-title":"J. Biol. Chem."},{"key":"BFnrrheum20104_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0083-6729(06)74016-X","volume":"74","author":"C Jacques","year":"2006","unstructured":"Jacques, C., Gosset, M., Berenbaum, F. & Gabay, C. The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation. Vitam. Horm. 74, 371\u2013403 (2006).","journal-title":"Vitam. Horm."},{"key":"BFnrrheum20104_CR12","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1016\/S0021-9258(18)61450-4","volume":"262","author":"B Mosley","year":"1987","unstructured":"Mosley, B. et al. The interleukin-1 receptor binds the human interleukin-1\u03b1 precursor but not the interleukin-1\u03b2 precursor. J. Biol. Chem. 262, 2941\u20132944 (1987).","journal-title":"J. Biol. Chem."},{"key":"BFnrrheum20104_CR13","doi-asserted-by":"crossref","first-page":"9437","DOI":"10.1016\/S0021-9258(19)76559-4","volume":"263","author":"RA Black","year":"1988","unstructured":"Black, R. A. et al. Generation of biologically active interleukin-1\u03b2 by proteolytic cleavage of the inactive precursor. J. Biol. Chem. 263, 9437\u20139442 (1988).","journal-title":"J. Biol. Chem."},{"key":"BFnrrheum20104_CR14","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/356768a0","volume":"356","author":"NA Thornberry","year":"1992","unstructured":"Thornberry, N. A. et al. A novel heterodimeric cysteine protease is required for interleukin-1\u03b2 processing in monocytes. Nature 356, 768\u2013774 (1992).","journal-title":"Nature"},{"key":"BFnrrheum20104_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/ni.1703","volume":"10","author":"L Franchi","year":"2009","unstructured":"Franchi, L., Eigenbrod, T., Mu\u00f1oz-Planillo, R. & Nunez, G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat. Immunol. 10, 241\u2013247 (2009).","journal-title":"Nat. Immunol."},{"key":"BFnrrheum20104_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1600-065X.2008.00730.x","volume":"227","author":"M Lamkanfi","year":"2009","unstructured":"Lamkanfi, M. & Dixit, V. M. Inflammasomes: guardians of cytosolic sanctity. Immunol. Rev. 227, 95\u2013105 (2009).","journal-title":"Immunol. Rev."},{"key":"BFnrrheum20104_CR17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev.immunol.021908.132715","volume":"27","author":"F Martinon","year":"2009","unstructured":"Martinon, F., Mayor, A. & Tschopp, J. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 27, 229\u2013265 (2009).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrrheum20104_CR18","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.immuni.2009.02.005","volume":"30","author":"IC Allen","year":"2009","unstructured":"Allen, I. C. et al. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity 30, 556\u2013565 (2009).","journal-title":"Immunity"},{"key":"BFnrrheum20104_CR19","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.immuni.2009.02.006","volume":"30","author":"PG Thomas","year":"2009","unstructured":"Thomas, P. G. et al. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity 30, 566\u2013575 (2009).","journal-title":"Immunity"},{"key":"BFnrrheum20104_CR20","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/nm.2028","volume":"15","author":"F Ghiringhelli","year":"2009","unstructured":"Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1\u03b2-dependent adaptive immunity against tumors. Nat. Med. 15, 1170\u20131178 (2009).","journal-title":"Nat. Med."},{"key":"BFnrrheum20104_CR21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1600-065X.2008.00624.x","volume":"223","author":"WP Arend","year":"2008","unstructured":"Arend, W. P., Palmer, G. & Gabay, C. IL-1, IL-18, and IL-33 families of cytokines. Immunol. Rev. 223, 20\u201338 (2008).","journal-title":"Immunol. Rev."},{"key":"BFnrrheum20104_CR22","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1182\/blood-2008-03-146720","volume":"113","author":"MG Netea","year":"2009","unstructured":"Netea, M. G. et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1\u03b2 in monocytes and macrophages. Blood 113, 2324\u20132335 (2009).","journal-title":"Blood"},{"key":"BFnrrheum20104_CR23","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cell.2007.12.040","volume":"132","author":"M Keller","year":"2008","unstructured":"Keller, M., Ruegg, A., Werner, S. & Beer, H. D. Active caspase-1 is a regulator of unconventional protein secretion. Cell 132, 818\u2013831 (2008).","journal-title":"Cell"},{"key":"BFnrrheum20104_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1023\/A:1020506300324","volume":"19","author":"G Fantuzzi","year":"1999","unstructured":"Fantuzzi, G. & Dinarello, C. A. Interleukin-18 and interleukin-1\u03b2: two cytokine substrates for ICE (caspase-1). J. Clin. Immunol. 19, 1\u201311 (1999).","journal-title":"J. Clin. Immunol."},{"key":"BFnrrheum20104_CR25","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.cell.2007.07.009","volume":"130","author":"FR Greten","year":"2007","unstructured":"Greten, F. R. et al. NF-\u03baB is a negative regulator of IL-1\u03b2 secretion as revealed by genetic and pharmacological inhibition of IKK\u03b2. Cell 130, 918\u2013931 (2007).","journal-title":"Cell"},{"key":"BFnrrheum20104_CR26","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1002\/art.24959","volume":"60","author":"M Guma","year":"2009","unstructured":"Guma, M. et al. Caspase 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation. Arthritis Rheum. 60, 3642\u20133650 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20104_CR27","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1002\/art.25006","volume":"60","author":"LA Joosten","year":"2009","unstructured":"Joosten, L. A. et al. Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1\u03b2. Arthritis Rheum. 60, 3651\u20133662 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20104_CR28","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nature08100","volume":"460","author":"G Guarda","year":"2009","unstructured":"Guarda, G. et al. T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes. Nature 460, 269\u2013273 (2009).","journal-title":"Nature"},{"key":"BFnrrheum20104_CR29","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1126\/science.275.5297.206","volume":"275","author":"Y Gu","year":"1997","unstructured":"Gu, Y. et al. Activation of interferon-\u03b3 inducing factor mediated by interleukin-1\u03b2 converting enzyme. Science 275, 206\u2013209 (1997).","journal-title":"Science"},{"key":"BFnrrheum20104_CR30","doi-asserted-by":"publisher","first-page":"19420","DOI":"10.1074\/jbc.M901744200","volume":"284","author":"D Talabot-Ayer","year":"2009","unstructured":"Talabot-Ayer, D., Lamacchia, C., Gabay, C. & Palmer, G. Interleukin-33 is biologically active independently of caspase-1 cleavage. J. Biol. Chem. 284, 19420\u201319426 (2009).","journal-title":"J. Biol. Chem."},{"key":"BFnrrheum20104_CR31","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1126\/science.2969618","volume":"241","author":"JE Sims","year":"1988","unstructured":"Sims, J. E. et al. cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science 241, 585\u2013589 (1988).","journal-title":"Science"},{"key":"BFnrrheum20104_CR32","doi-asserted-by":"crossref","first-page":"re3","DOI":"10.1126\/stke.2003.171.re3","volume":"2003","author":"A Dunne","year":"2003","unstructured":"Dunne, A. & O'Neill, L. A. The interleukin-1 receptor\/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci. STKE 2003, re3 (2003).","journal-title":"Sci. STKE"},{"key":"BFnrrheum20104_CR33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0083-6729(06)74009-2","volume":"74","author":"D Boraschi","year":"2006","unstructured":"Boraschi, D. & Tagliabue, A. The interleukin-1 receptor family. Vitam. Horm. 74, 229\u2013254 (2006).","journal-title":"Vitam. Horm."},{"key":"BFnrrheum20104_CR34","doi-asserted-by":"publisher","first-page":"13757","DOI":"10.1074\/jbc.270.23.13757","volume":"270","author":"SA Greenfeder","year":"1995","unstructured":"Greenfeder, S. A. et al. Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J. Biol. Chem. 270, 13757\u201313765 (1995).","journal-title":"J. Biol. Chem."},{"key":"BFnrrheum20104_CR35","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.immuni.2005.11.011","volume":"24","author":"LS Miller","year":"2006","unstructured":"Miller, L. S. et al. MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus. Immunity 24, 79\u201391 (2006).","journal-title":"Immunity"},{"key":"BFnrrheum20104_CR36","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095","volume":"87","author":"CA Dinarello","year":"1996","unstructured":"Dinarello, C. A. Biologic basis for interleukin-1 in disease. Blood 87, 2095\u20132147 (1996).","journal-title":"Blood"},{"key":"BFnrrheum20104_CR37","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.immuni.2009.02.007","volume":"30","author":"Y Chung","year":"2009","unstructured":"Chung, Y. et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 30, 576\u2013587 (2009).","journal-title":"Immunity"},{"key":"BFnrrheum20104_CR38","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/ni1496","volume":"8","author":"EV Acosta-Rodriguez","year":"2007","unstructured":"Acosta-Rodriguez, E. V., Napolitani, G., Lanzavecchia, A. & Sallusto, F. Interleukins 1\u03b2 and 6 but not transforming growth factor-\u03b2 are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 8, 942\u2013949 (2007).","journal-title":"Nat. Immunol."},{"key":"BFnrrheum20104_CR39","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.4049\/jimmunol.134.6.3868","volume":"134","author":"WP Arend","year":"1985","unstructured":"Arend, W. P., Joslin, F. G. & Massoni, R. J. Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor. J. Immunol. 134, 3868\u20133875 (1985).","journal-title":"J. Immunol."},{"key":"BFnrrheum20104_CR40","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1172\/JCI112669","volume":"78","author":"JF Balavoine","year":"1986","unstructured":"Balavoine, J. F. et al. Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s). J. Clin. Invest. 78, 1120\u20131124 (1986).","journal-title":"J. Clin. Invest."},{"key":"BFnrrheum20104_CR41","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1172\/JCI114622","volume":"85","author":"WP Arend","year":"1990","unstructured":"Arend, W. P., Welgus, H. G., Thompson, R. C. & Eisenberg, S. P. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J. Clin. Invest. 85, 1694\u20131697 (1990).","journal-title":"J. Clin. Invest."},{"key":"BFnrrheum20104_CR42","first-page":"R442","volume":"261","author":"E Fischer","year":"1991","unstructured":"Fischer, E. et al. Comparison between effects of interleukin-1 alpha administration and sublethal endotoxemia in primates. Am. J. Physiol. 261, R442\u2013R452 (1991).","journal-title":"Am. J. Physiol."},{"key":"BFnrrheum20104_CR43","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nrrheum.2009.177","volume":"9","author":"C Gabay","year":"2009","unstructured":"Gabay, C. & Palmer, G. Mutations in the IL-1RN locus lead to autoinflammation. Nat. Rev. Rheumatol. 9, 480\u2013482 (2009).","journal-title":"Nat. Rev. Rheumatol."},{"key":"BFnrrheum20104_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1006\/clin.1994.1100","volume":"72","author":"JE Sims","year":"1994","unstructured":"Sims, J. E., Giri, J. G. & Dower, S. K. The two interleukin-1 receptors play different roles in IL-1 actions. Clin. Immunol. Immunopathol. 72, 9\u201314 (1994).","journal-title":"Clin. Immunol. Immunopathol."},{"key":"BFnrrheum20104_CR45","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/0167-5699(94)90217-8","volume":"15","author":"F Colotta","year":"1994","unstructured":"Colotta, F., Dower, S. K., Sims, J. E. & Mantovani, A. The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1. Immunol. Today 15, 562\u2013566 (1994).","journal-title":"Immunol. Today"},{"key":"BFnrrheum20104_CR46","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.it.2009.06.001","volume":"30","author":"C Garlanda","year":"2009","unstructured":"Garlanda, C., Anders, H. J. & Mantovani, A. TIR8\/SIGIRR: an IL-1R\/TLR family member with regulatory functions in inflammation and T cell polarization. Trends Immunol. 30, 439\u2013446 (2009).","journal-title":"Trends Immunol."},{"key":"BFnrrheum20104_CR47","doi-asserted-by":"publisher","first-page":"5277","DOI":"10.4049\/jimmunol.164.10.5277","volume":"164","author":"LE Jensen","year":"2000","unstructured":"Jensen, L. E., Muzio, M., Mantovani, A. & Whitehead, A. S. IL-1 signaling cascade in liver cells and the involvement of a soluble form of the IL-1 receptor accessory protein. J. Immunol. 164, 5277\u20135286 (2000).","journal-title":"J. Immunol."},{"key":"BFnrrheum20104_CR48","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1074-7613(02)00514-9","volume":"18","author":"DE Smith","year":"2003","unstructured":"Smith, D. E. et al. The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity 18, 87\u201396 (2003).","journal-title":"Immunity"},{"key":"BFnrrheum20104_CR49","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.immuni.2009.03.020","volume":"30","author":"DE Smith","year":"2009","unstructured":"Smith, D. E. et al. A central nervous system-restricted isoform of the interleukin-1 receptor accessory protein modulates neuronal responses to interleukin-1. Immunity 30, 817\u2013831 (2009).","journal-title":"Immunity"},{"key":"BFnrrheum20104_CR50","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1084\/jem.20021790","volume":"197","author":"K Burns","year":"2003","unstructured":"Burns, K. et al. Inhibition of interleukin 1 receptor\/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J. Exp. Med. 197, 263\u2013268 (2003).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum20104_CR51","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0092-8674(02)00827-9","volume":"110","author":"K Kobayashi","year":"2002","unstructured":"Kobayashi, K. et al. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110, 191\u2013202 (2002).","journal-title":"Cell"},{"key":"BFnrrheum20104_CR52","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/BOR.0b013e3282fa13b4","volume":"20","author":"A Finckh","year":"2008","unstructured":"Finckh, A. & Gabay, C. At the horizon of innovative therapy in rheumatology: new biologic agents. Curr. Opin. Rheumatol. 20, 269\u2013275 (2008).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum20104_CR53","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2","volume":"41","author":"B Bresnihan","year":"1998","unstructured":"Bresnihan, B. et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41, 2196\u20132204 (1998).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20104_CR54","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/art.10141","volume":"46","author":"S Cohen","year":"2002","unstructured":"Cohen, S. et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 614\u2013624 (2002).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20104_CR55","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P","volume":"43","author":"Y Jiang","year":"2000","unstructured":"Jiang, Y. et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 43, 1001\u20131009 (2000).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20104_CR56","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/art.20221","volume":"50","author":"MC Genovese","year":"2004","unstructured":"Genovese, M. C. et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 50, 1412\u20131419 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20104_CR57","doi-asserted-by":"publisher","first-page":"R67","DOI":"10.1186\/ar2438","volume":"10","author":"R Alten","year":"2008","unstructured":"Alten, R. et al. The human anti-IL-1\u03b2 monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res. Ther. 10, R67 (2008).","journal-title":"Arthritis Res. Ther."},{"issue":"Suppl.","key":"BFnrrheum20104_CR58","first-page":"S535","volume":"58","author":"WG Bensen","year":"2008","unstructured":"Bensen, W. G. et al. Results of a phase 2 randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R type I) in patients with rheumatoid arthritis [abstract #994]. Arthritis Rheum. 58 (Suppl.), S535 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20104_CR59","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/art.1780390212","volume":"39","author":"BE Drevlow","year":"1996","unstructured":"Drevlow, B. E. et al. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum. 39, 257\u2013265 (1996).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20104_CR60","first-page":"3415","volume":"46","author":"K Pavelka","year":"2002","unstructured":"Pavelka, K. et al. Clinical effects of pralnacasan (PRAL), an orally-active interleukin-1\u03b2 converting enzyme (ICE) inhibitor, in a 285 patient Phase II trial in rheumatoid arthritis [abstract LB02]. Arthritis Rheum. 46, 3415 (2002).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20104_CR61","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S1074-7613(04)00046-9","volume":"20","author":"L Agostini","year":"2004","unstructured":"Agostini, L. et al. NLRP3 forms an IL-1\u03b2-processing inflammasome with increased activity in Muckle\u2013Wells autoinflammatory disorder. Immunity 20, 319\u2013325 (2004).","journal-title":"Immunity"},{"key":"BFnrrheum20104_CR62","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(04)17401-1","volume":"364","author":"HM Hoffman","year":"2004","unstructured":"Hoffman, H. M. et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364, 1779\u20131785 (2004).","journal-title":"Lancet"},{"key":"BFnrrheum20104_CR63","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1056\/NEJM200306193482523","volume":"348","author":"PN Hawkins","year":"2003","unstructured":"Hawkins, P. N., Lachmann, H. J. & McDermott, M. F. Interleukin-1-receptor antagonist in the Muckle\u2013Wells syndrome. N. Engl. J. Med. 348, 2583\u20132584 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum20104_CR64","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1002\/art.23687","volume":"58","author":"HM Hoffman","year":"2008","unstructured":"Hoffman, H. M. et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 58, 2443\u20132452 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20104_CR65","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","volume":"360","author":"HJ Lachmann","year":"2009","unstructured":"Lachmann, H. J. et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360, 2416\u20132425 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum20104_CR66","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1056\/NEJMoa0807865","volume":"360","author":"I Aksentijevich","year":"2009","unstructured":"Aksentijevich, I. et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 360, 2426\u20132437 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum20104_CR67","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1056\/NEJMoa0809568","volume":"360","author":"S Reddy","year":"2009","unstructured":"Reddy, S. et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N. Engl. J. Med. 360, 2438\u20132444 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum20104_CR68","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1182\/blood-2008-01-134932","volume":"112","author":"JJ Chae","year":"2008","unstructured":"Chae, J. J. et al. The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-\u03baB through its N-terminal fragment. Blood 112, 1794\u20131803 (2008).","journal-title":"Blood"},{"key":"BFnrrheum20104_CR69","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S1097-2765(03)00056-X","volume":"11","author":"JJ Chae","year":"2003","unstructured":"Chae, J. J. et al. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol. Cell 11, 591\u2013604 (2003).","journal-title":"Mol. Cell"},{"key":"BFnrrheum20104_CR70","doi-asserted-by":"publisher","first-page":"9982","DOI":"10.1073\/pnas.0602081103","volume":"103","author":"JJ Chae","year":"2006","unstructured":"Chae, J. J. et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1\u03b2 production. Proc. Natl Acad. Sci. USA 103, 9982\u20139987 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum20104_CR71","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/sj.cdd.4401734","volume":"13","author":"JW Yu","year":"2006","unstructured":"Yu, J. W. et al. Cryopyrin and pyrin activate caspase-1, but not NF-\u03baB, via ASC oligomerization. Cell Death Differ. 13, 236\u2013249 (2006).","journal-title":"Cell Death Differ."},{"key":"BFnrrheum20104_CR72","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.4049\/jimmunol.179.2.1274","volume":"179","author":"S Seshadri","year":"2007","unstructured":"Seshadri, S., Duncan, M. D., Hart, J. M., Gavrilin, M. A. & Wewers, M. D. Pyrin levels in human monocytes and monocyte-derived macrophages regulate IL-1\u03b2 processing and release. J. Immunol. 179, 1274\u20131281 (2007).","journal-title":"J. Immunol."},{"key":"BFnrrheum20104_CR73","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jbspin.2008.04.001","volume":"75","author":"R Roldan","year":"2008","unstructured":"Roldan, R., Ruiz, A. M., Miranda, M. D. & Collantes, E. Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine. Joint Bone Spine 75, 504\u2013505 (2008).","journal-title":"Joint Bone Spine"},{"key":"BFnrrheum20104_CR74","doi-asserted-by":"publisher","first-page":"13501","DOI":"10.1073\/pnas.2135380100","volume":"100","author":"NG Shoham","year":"2003","unstructured":"Shoham, N. G. et al. Pyrin binds the PSTPIP1\/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc. Natl Acad. Sci. USA 100, 13501\u201313506 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum20104_CR75","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.molcel.2007.08.029","volume":"28","author":"JW Yu","year":"2007","unstructured":"Yu, J. W. et al. Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants. Mol. Cell 28, 214\u2013227 (2007).","journal-title":"Mol. Cell"},{"key":"BFnrrheum20104_CR76","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/rheumatology\/keh479","volume":"44","author":"MP Dierselhuis","year":"2005","unstructured":"Dierselhuis, M. P., Frenkel, J., Wulffraat, N. M. & Boelens, J. J. Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology (Oxford) 44, 406\u2013408 (2005).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum20104_CR77","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.1002\/art.22194","volume":"54","author":"SH Mandey","year":"2006","unstructured":"Mandey, S. H., Kuijk, L. M., Frenkel, J. & Waterham, H. R. A role for geranylgeranylation in interleukin-1\u03b2 secretion. Arthritis Rheum. 54, 3690\u20133695 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20104_CR78","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1182\/blood-2008-03-144667","volume":"112","author":"LM Kuijk","year":"2008","unstructured":"Kuijk, L. M. et al. HMG-CoA reductase inhibition induces IL-1\u03b2 release through Rac1\/PI3K\/PKB-dependent caspase-1 activation. Blood 112, 3563\u20133573 (2008).","journal-title":"Blood"},{"key":"BFnrrheum20104_CR79","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s10545-006-0408-7","volume":"29","author":"M Cailliez","year":"2006","unstructured":"Cailliez, M. et al. Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. J. Inherit. Metab. Dis. 29, 763 (2006).","journal-title":"J. Inherit. Metab. Dis."},{"key":"BFnrrheum20104_CR80","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1182\/blood-2005-11-006783","volume":"108","author":"AA Lobito","year":"2006","unstructured":"Lobito, A. A. et al. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 108, 1320\u20131327 (2006).","journal-title":"Blood"},{"key":"BFnrrheum20104_CR81","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1002\/art.22740","volume":"56","author":"I Todd","year":"2007","unstructured":"Todd, I. et al. Mutant tumor necrosis factor receptor associated with tumor necrosis factor receptor-associated periodic syndrome is altered antigenically and is retained within patients' leukocytes. Arthritis Rheum. 56, 2765\u20132773 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20104_CR82","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1002\/art.23475","volume":"58","author":"M Gattorno","year":"2008","unstructured":"Gattorno, M. et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 58, 1516\u20131520 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20104_CR83","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev.immunol.25.022106.141627","volume":"27","author":"SL Masters","year":"2009","unstructured":"Masters, S. L., Simon, A., Aksentijevich, I. & Kastner, D. L. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu. Rev. Immunol. 27, 621\u2013668 (2009).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrrheum20104_CR84","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/art.24222","volume":"60","author":"TM Martin","year":"2009","unstructured":"Martin, T. M. et al. The NOD2 defect in Blau syndrome does not result in excess interleukin-1 activity. Arthritis Rheum. 60, 611\u2013618 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20104_CR85","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.semarthrit.2007.04.001","volume":"37","author":"HD de Koning","year":"2007","unstructured":"de Koning, H. D. et al. Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin. Arthritis Rheum. 37, 137\u2013148 (2007).","journal-title":"Semin. Arthritis Rheum."},{"key":"BFnrrheum20104_CR86","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1084\/jem.20050473","volume":"201","author":"V Pascual","year":"2005","unstructured":"Pascual, V., Allantaz, F., Arce, E., Punaro, M. & Banchereau, J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201, 1479\u20131486 (2005).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum20104_CR87","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/art.23437","volume":"58","author":"M Gattorno","year":"2008","unstructured":"Gattorno, M. et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 58, 1505\u20131515 (2008).","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 3","key":"BFnrrheum20104_CR88","first-page":"170","volume":"68","author":"N Ruperto","year":"2009","unstructured":"Ruperto, N. et al. A phase II trial with Canakinumab (ACZ885), a new IL-1-beta blocking monoclonal antibody, to evaluate safety and preliminary efficacy in children with systemic juvenile idiopathic arthritis (SJIA) [abstract #OP-0298]. Ann. Rheum. Dis. 68 (Suppl. 3), 170 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum20104_CR89","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/ncprheum0919","volume":"4","author":"A Kelly","year":"2008","unstructured":"Kelly, A. & Ramanan, A. V. A case of macrophage activation syndrome successfully treated with anakinra. Nat. Clin. Pract. Rheumatol. 4, 615\u2013620 (2008).","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"BFnrrheum20104_CR90","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/ard.2007.076034","volume":"67","author":"T Lequerre","year":"2008","unstructured":"Lequerre, T. et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann. Rheum. Dis. 67, 302\u2013308 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum20104_CR91","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NLRP3 inflammasome. Nature 440, 237\u2013241 (2006).","journal-title":"Nature"},{"key":"BFnrrheum20104_CR92","doi-asserted-by":"publisher","first-page":"R28","DOI":"10.1186\/ar2143","volume":"9","author":"A So","year":"2007","unstructured":"So, A., De Smedt, T., Revaz, S. & Tschopp, J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 9, R28 (2007).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum20104_CR93","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jbspin.2009.01.001","volume":"76","author":"N Announ","year":"2009","unstructured":"Announ, N., Palmer, G., Guerne, P. A. & Gabay, C. Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine 76, 424\u2013426 (2009).","journal-title":"Joint Bone Spine"},{"key":"BFnrrheum20104_CR94","first-page":"4231","volume":"56","author":"R Terkeltaub","year":"2007","unstructured":"Terkeltaub, R. et al. Placebo-controlled pilot study of Rilonacept (IL-1 trap), a long acting IL-1 inhibitor, in refractory chronic active gouty arthritis [abstract LB518-L2]. Arthritis Rheum. 56, 4231\u20134232 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20104_CR95","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/art.24174","volume":"60","author":"P Picco","year":"2009","unstructured":"Picco, P. et al. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1\u03b2 receptor antagonist (anakinra): an unrecognized autoinflammatory disease? Arthritis Rheum. 60, 264\u2013268 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20104_CR96","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1056\/NEJMoa065213","volume":"356","author":"CM Larsen","year":"2007","unstructured":"Larsen, C. M. et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356, 1517\u20131526 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum20104_CR97","doi-asserted-by":"publisher","first-page":"114","DOI":"10.4065\/84.2.114","volume":"84","author":"JA Lust","year":"2009","unstructured":"Lust, J. A. et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1\u03b2-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin. Proc. 84, 114\u2013122 (2009).","journal-title":"Mayo Clin. Proc."},{"key":"BFnrrheum20104_CR98","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.cardiores.2005.01.008","volume":"66","author":"F Merhi-Soussi","year":"2005","unstructured":"Merhi-Soussi, F. et al. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc. Res. 66, 583\u2013593 (2005).","journal-title":"Cardiovasc. Res."},{"key":"BFnrrheum20104_CR99","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/art.1780390513","volume":"39","author":"LA Joosten","year":"1996","unstructured":"Joosten, L. A., Helsen, M. M., van de Loo, F. A. & van den Berg, W. B. Anticytokine treatment of established type II collagen-induced arthritis in DBA\/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha\/beta, and IL-1Ra. Arthritis Rheum. 39, 797\u2013809 (1996).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20104_CR100","first-page":"1338","volume":"22","author":"EC Arner","year":"1995","unstructured":"Arner, E. C., Harris, R. R., DiMeo, T. M., Collins, R. C. & Galbraith, W. Interleukin-1 receptor antagonist inhibits proteoglycan breakdown in antigen induced but not polycation induced arthritis in the rabbit. J. Rheumatol. 22, 1338\u20131346 (1995).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum20104_CR101","first-page":"2250","volume":"22","author":"PL Van Lent","year":"1995","unstructured":"Van Lent, P. L. et al. Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice. J. Rheumatol. 22, 2250\u20132258 (1995).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum20104_CR102","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1006\/cyto.1998.0372","volume":"10","author":"S Kuiper","year":"1998","unstructured":"Kuiper, S. et al. Different roles of tumour necrosis factor alpha and interleukin 1 in murine streptococcal cell wall arthritis. Cytokine 10, 690\u2013702 (1998).","journal-title":"Cytokine"},{"key":"BFnrrheum20104_CR103","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1002\/1529-0131(199810)41:10<1798::AID-ART11>3.0.CO;2-L","volume":"41","author":"Y Ma","year":"1998","unstructured":"Ma, Y. et al. Altered susceptibility to collagen-induced arthritis in transgenic mice with aberrant expression of interleukin-1 receptor antagonist. Arthritis Rheum. 41, 1798\u20131805 (1998).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20104_CR104","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/immu.200310018","volume":"33","author":"G Palmer","year":"2003","unstructured":"Palmer, G. et al. Mice transgenic for intracellular interleukin-1 receptor antagonist type 1 are protected from collagen-induced arthritis. Eur. J. Immunol. 33, 434\u2013440 (2003).","journal-title":"Eur. J. Immunol."},{"key":"BFnrrheum20104_CR105","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/art.1780400517","volume":"40","author":"AC Bakker","year":"1997","unstructured":"Bakker, A. C. et al. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum. 40, 893\u2013900 (1997).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20104_CR106","first-page":"1118","volume":"25","author":"KH Nguyen","year":"1998","unstructured":"Nguyen, K. H. et al. Direct synovial gene transfer with retroviral vectors in rat adjuvant arthritis. J. Rheumatol. 25, 1118\u20131125 (1998).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum20104_CR107","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/1529-0131(200002)43:2<289::AID-ANR8>3.0.CO;2-H","volume":"43","author":"RY Pan","year":"2000","unstructured":"Pan, R. Y. et al. Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist. Arthritis Rheum. 43, 289\u2013297 (2000).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20104_CR108","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/sj.gt.3301014","volume":"6","author":"TJ Oligino","year":"1996","unstructured":"Oligino, T. J., Ghivizzani, S. & Wolfe, D. Intra-articular delivery of a herpes simplex virus IL-1Ra gene vector reduces inflammation in a rabbit model of arthritis. Gene Ther. 6, 1713\u20131720 (1996).","journal-title":"Gene Ther."},{"key":"BFnrrheum20104_CR109","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.4049\/jimmunol.156.9.3558","volume":"156","author":"K Otani","year":"1996","unstructured":"Otani, K. et al. Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. J. Immunol. 156, 3558\u20133562 (1996).","journal-title":"J. Immunol."},{"key":"BFnrrheum20104_CR110","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.4049\/jimmunol.158.7.3492","volume":"158","author":"U Muller-Ladner","year":"1997","unstructured":"Muller-Ladner, U. et al. Human IL-1Ra gene transfer into human synovial fibroblasts is chondroprotective. J. Immunol. 158, 3492\u20133498 (1997).","journal-title":"J. Immunol."},{"key":"BFnrrheum20104_CR111","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nm811","volume":"9","author":"AN Economides","year":"2003","unstructured":"Economides, A. N. et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat. Med. 9, 47\u201352 (2003).","journal-title":"Nat. Med."},{"key":"BFnrrheum20104_CR112","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1365-2249.1994.tb06517.x","volume":"95","author":"WB van den Berg","year":"1994","unstructured":"van den Berg, W. B., Joosten, L. A., Helsen, M. & van de Loo, F. A. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin. Exp. Immunol. 95, 237\u2013243 (1994).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrrheum20104_CR113","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1084\/jem.20021850","volume":"197","author":"JY Choe","year":"2003","unstructured":"Choe, J. Y., Crain, B., Wu, S. R. & Corr, M. Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by toll-like receptor 4 signaling. J. Exp. Med. 197, 537\u2013542 (2003).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum20104_CR114","doi-asserted-by":"publisher","first-page":"C113","DOI":"10.1007\/BF01972739","volume":"39","author":"HU Schorlemmer","year":"1993","unstructured":"Schorlemmer, H. U., Kanzy, E. J., Langner, K. D. & Kurrle, R. Immunomodulatory activity of recombinant IL-1 receptor (IL-1-R) on models of experimental rheumatoid arthritis. Agents Actions 39, C113\u2013C116 (1993).","journal-title":"Agents Actions"},{"key":"BFnrrheum20104_CR115","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/rheumatology\/38.5.401","volume":"38","author":"J Dawson","year":"1999","unstructured":"Dawson, J. et al. Effects of soluble interleukin-1 type II receptor on rabbit antigen-induced arthritis: clinical, biochemical and histological assessment. Rheumatology (Oxford) 38, 401\u2013406 (1999).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum20104_CR116","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/1521-4141(200003)30:3<867::AID-IMMU867>3.0.CO;2-M","volume":"30","author":"N Bessis","year":"2000","unstructured":"Bessis, N. et al. The type II decoy receptor of IL-1 inhibits murine collagen-induced arthritis. Eur. J. Immunol. 30, 867\u2013875 (2000).","journal-title":"Eur. J. Immunol."},{"key":"BFnrrheum20104_CR117","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1002\/art.21108","volume":"52","author":"RL Smeets","year":"2005","unstructured":"Smeets, R. L. et al. Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist. Arthritis Rheum. 52, 2202\u20132211 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20104_CR118","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1002\/art.11234","volume":"48","author":"RL Smeets","year":"2003","unstructured":"Smeets, R. L. et al. Effectiveness of the soluble form of the interleukin-1 receptor accessory protein as an inhibitor of interleukin-1 in collagen-induced arthritis. Arthritis Rheum. 48, 2949\u20132958 (2003).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20104_CR119","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1006\/cyto.1996.0052","volume":"8","author":"G Ku","year":"1996","unstructured":"Ku, G., Faust, T., Lauffer, L. L., Livingston, D. J. & Harding, M. W. Interleukin-1\u03b2 converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice. Cytokine 8, 377\u2013386 (1996).","journal-title":"Cytokine"}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2010.4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2010.4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2010.4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T08:43:36Z","timestamp":1685436216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2010.4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,23]]},"references-count":119,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["BFnrrheum20104"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2010.4","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,23]]},"assertion":[{"value":"23 February 2010","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}